YHC1154

YHC1154 is a preclinical-stage oncology drug candidate being developed by Yuhan Corporation for the treatment of solid tumors. It is part of Yuhan's early-stage discovery pipeline, which includes a series of 'YHC' assets focused on novel cancer therapies. As of early 2026, YHC1154 remains in the preclinical phase of development, and its specific biological target and therapeutic modality have not been publicly disclosed. The program is part of Yuhan's broader strategy to expand its oncology portfolio following the success of its EGFR inhibitor, lazertinib, and is likely being evaluated for its potential to address unmet needs in various solid tumor indications.